Sumitomo Pharma shares plunge nearly 16% despite greenlight for Parkinson's treatment (2026-02-20)
Shares of Japan's Sumitomo Pharma fell over 15% on the back of profit-taking after a specialist panel endorsed its iPS cell-based therapy for Parkinson's disease.